Literature DB >> 19224124

Association of antiphosphatidylserine/prothrombin antibodies with neuropsychiatric systemic lupus erythematosus.

Tomoko Syuto1, Akira Shimizu, Yuko Takeuchi, Setsuko Tanaka, Michiko Hasegawa, Yayoi Nagai, Atsushi Tamura, Osamu Ishikawa.   

Abstract

Neuropsychiatric manifestations in patients with systemic lupus erythematosus (SLE) are well-recognized symptoms although the pathophysiology of neuropsychiatric SLE (NPSLE) is unclear. Since an association with antiphospholipid antibodies has been reported, we examined the prevalence of antiphosphatidylserine-prothrombin antibodies (anti-PS/PT Abs), lupus anticoagulant (LA), anticardiolipin/beta2-glycoprotein I antibodies (anti-beta2-GPI Abs), and antiribosomal P protein antibodies (antiribosomal P Abs) in 68 SLE patients and analyzed their associations with neuropsychiatric manifestations. The prevalence of LA was significantly higher in the patients with neuropsychiatric (NP) features than those without NP features (P < 0.02). The levels of anti-PS/PT antibody were also significantly higher in the patients with NP features than those without NP features (P < 0.01). The results indicate that LA positivity and higher levels of anti-PS/PT antibody can be predictive markers for NPSLE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224124     DOI: 10.1007/s10067-009-1123-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

1.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

Review 2.  Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome.

Authors:  Gisele Zandman-Goddard; Joab Chapman; Yehuda Shoenfeld
Journal:  Semin Arthritis Rheum       Date:  2007-01-26       Impact factor: 5.532

Review 3.  The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.

Authors: 
Journal:  Arthritis Rheum       Date:  1999-04

4.  Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.

Authors:  John G Hanly; Grace McCurdy; Lisa Fougere; Jo-Anne Douglas; Kara Thompson
Journal:  J Rheumatol       Date:  2004-11       Impact factor: 4.666

5.  Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies.

Authors:  Giovanni Sanna; Maria L Bertolaccini; Maria J Cuadrado; Hana Laing; Munther A Khamashta; Alessandro Mathieu; Graham R V Hughes
Journal:  J Rheumatol       Date:  2003-05       Impact factor: 4.666

6.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

7.  Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies--Co-existence of these antibodies enhances ADP-induced platelet activation in vitro.

Authors:  Junzo Nojima; Hirohiko Kuratsune; Etsuji Suehisa; Teruo Kitani; Yoshinori Iwatani; Yuzuru Kanakura
Journal:  Thromb Haemost       Date:  2004-05       Impact factor: 5.249

8.  The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus.

Authors:  Wilmer L Sibbitt; John R Brandt; Courtney R Johnson; Marcos E Maldonado; Samir R Patel; Corey C Ford; Arthur D Bankhurst; William M Brooks
Journal:  J Rheumatol       Date:  2002-07       Impact factor: 4.666

9.  Arteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus.

Authors:  J Nojima; Y Masuda; Y Iwatani; H Kuratsune; Y Watanabe; E Suehisa; T Takano; Y Hidaka; Y Kanakura
Journal:  Rheumatology (Oxford)       Date:  2008-03-27       Impact factor: 7.580

10.  A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus.

Authors:  Tadej Avcin; Susanne M Benseler; Pascal N Tyrrell; Sasa Cucnik; Earl D Silverman
Journal:  Arthritis Rheum       Date:  2008-02-15
View more
  5 in total

1.  Libman-Sacks endocarditis and embolic cerebrovascular disease.

Authors:  Carlos A Roldan; Wilmer L Sibbitt; Clifford R Qualls; Rex E Jung; Ernest R Greene; Charles M Gasparovic; Reyaad A Hayek; Gerald A Charlton; Kendall Crookston
Journal:  JACC Cardiovasc Imaging       Date:  2013-09

2.  Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE.

Authors:  Michael E Luggen; Gaurav Gulati; Bin Zhang; Rohan A Willis; Emilio B Gonzalez
Journal:  Clin Rheumatol       Date:  2015-11-12       Impact factor: 2.980

3.  Neuropsychiatric lupus.

Authors:  Amal Alkhotani
Journal:  Sultan Qaboos Univ Med J       Date:  2013-02-27

4.  The introduction of anti-phosphatidylserine/prothrombin autoantibodies in the laboratory diagnostic process of anti-phospholipid antibody syndrome: 6 months of observation.

Authors:  Martina Fabris; Roberta Giacomello; Alessandra Poz; Lisa Pantarotto; Nicolanna Tanzi; Francesco Curcio; Elio Tonutti
Journal:  Auto Immun Highlights       Date:  2014-08-14

5.  The role of anti-phosphatidylserine/prothrombin antibodies in thrombotic manifestations of systemic lupus erythematosus patients.

Authors:  Konstantinos Tselios; Alexandros Sarantopoulos; Ioannis Gkougkourellas; Panagiota Boura
Journal:  Front Neurol       Date:  2013-06-04       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.